The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I).

##STR00001##

A nonlinear light absorption material includes a compound represented by the following formula (1) as a main component:

##STR00001##

in the formula (1), R.sup.1 to R.sup.10 are each independently a hydrogen atom, a halogen atom, a saturated hydrocarbon group, a halogenated alkyl group, an unsaturated hydrocarbon group, a hydroxyl group, a carboxyl group, an alkoxycarbonyl group, an aldehyde group, an acyl group, an amide group, a nitrile group, an alkoxy group, an acyloxy group, a thiol group, an alkylthio group, a sulfonate group, an acylthio group, an alkylsulfonyl group, a sulfonamide group, a primary amino group, a secondary amino group, a tertiary amino group, or a nitro group.

Methods of forming crystals including, for example, methods of forming crystals using a nanoporous matrix, and associated materials, articles, and systems are generally provided. Advantageously, in some embodiments, the methods of forming crystals described herein provide crystal formation of a target molecule from a solution initially at an undersaturated state with respect to the target molecule. In some embodiments, a method involves obtaining a solution of a target molecule, where in some cases the solution is at an undersaturated state with respect to the target molecule; and exposing the solution to a functionalized nanoporous matrix under conditions that promote crystal formation of the target molecule. In some cases, the nanoporous matrix is functionalized with an antisolvent group.

Methods of forming crystals including, for example, methods of forming crystals using a nanoporous matrix, and associated materials, articles, and systems are generally provided. Advantageously, in some embodiments, the methods of forming crystals described herein provide crystal formation of a target molecule from a solution initially at an undersaturated state with respect to the target molecule. In some embodiments, a method involves obtaining a solution of a target molecule, where in some cases the solution is at an undersaturated state with respect to the target molecule; and exposing the solution to a functionalized nanoporous matrix under conditions that promote crystal formation of the target molecule. In some cases, the nanoporous matrix is functionalized with an antisolvent group.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The invention relates to a method for the production of acetylsalicylic acid lysinate, optionally lysine acetylsalicylate.glycine, comprising the following steps: a) providing a solution of acetylsalicylic acid in ethanol; b) providing an aqueous solution of lysine; c) combining the solutions of step a) and b) to form a mixture; d) optionally stirring the mixture; e) adding acetone to the mixture; f) incubating the mixture, to allow the formation of a acetylsalicylic acid lysinate product; g) isolating the acetylsalicylic acid lysinate product; wherein acetylsalicylic acid is used in excess compared to lysine and wherein no seed crystals are added to the mixture; and optionally the following further steps: h) providing a recrystallized glycine; wherein the glycine has been recrystallized with the following steps: h1) dissolving glycine in water; h2) adding acetone to the glycine solution; h3) stirring the mixture until a precipitate is obtained; i) combining the recrystallized glycine of step h) with the acetylsalicylic acid lysinate product of step g) to obtain lysine acetylsalicylate.glycine (LASAG) particles.

The invention relates to a method for the production of acetylsalicylic acid lysinate, optionally lysine acetylsalicylate.glycine, comprising the following steps: a) providing a solution of acetylsalicylic acid in ethanol; b) providing an aqueous solution of lysine; c) combining the solutions of step a) and b) to form a mixture; d) optionally stirring the mixture; e) adding acetone to the mixture; f) incubating the mixture, to allow the formation of a acetylsalicylic acid lysinate product; g) isolating the acetylsalicylic acid lysinate product; wherein acetylsalicylic acid is used in excess compared to lysine and wherein no seed crystals are added to the mixture; and optionally the following further steps: h) providing a recrystallized glycine; wherein the glycine has been recrystallized with the following steps: h1) dissolving glycine in water; h2) adding acetone to the glycine solution; h3) stirring the mixture until a precipitate is obtained; i) combining the recrystallized glycine of step h) with the acetylsalicylic acid lysinate product of step g) to obtain lysine acetylsalicylate.glycine (LASAG) particles.

The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.

The present invention is directed to a method for preparing a final phenolic product from biomass comprising the steps of providing a furanic compound obtainable from biomass; reacting the furanic compound with a dienophile to obtain a phenolic compound; reacting the phenolic compound further to obtain the final phenolic product.